AI and health tech lead March's IPO surge with CoreWeave securing a $12B OpenAI contract ahead of its New York debut, while Hinge Health files to raise $500M. The pipeline remains robust across regions with StubHub targeting $1B+ in the US, South Korea's DN Solutions seeking $1B in Seoul, and Air Baltic planning a London listing. MENA markets show strength with Umm Al Qura's offering attracting over $1B from retail investors alone, while China's tech sector sees renewed listing momentum.

IPOX® CEO Josef Schuster was recently interviewed by the Financial Times regarding Venture Global's troubling market performance. Following a 36% single-day stock plunge, Schuster provided expert analysis on the LNG producer's IPO struggles.

AI-powered CoreWeave targets $4B raise at $35B valuation, while fintech giant Klarna prepares $1B+ New York debut. Tech dominates upcoming listings with cryptocurrency exchanges Gemini and Kraken, design platform Figma, and communications app Discord all planning 2025 offerings. Europe and Asia-Pacific markets see continued activity with healthcare, finance and industrial firms leading the charge.

IPOX® CEO Josef Schuster was interviewed by Bloomberg to discuss Venture Global's aftermarket performance following its recent IPO. Schuster provided insights into the challenging market conditions faced by Venture Global, emphasizing its notably poor stock performance compared to other major energy IPOs in recent decades.

Global IPO activity is spread across regions. In the U.S., CoreWeave and Holcim's Amrize are planning major listings. Europe sees Olam Food Ingredients gearing up for a London IPO and Northern Data for Frankfurt uplisting. Asia-Pacific is vibrant with Mixue's Hong Kong IPO seeing huge demand and JX Advanced Metals launching a large Tokyo IPO. Saudi Arabia's Umm Al Qura IPO in MENA was heavily oversubscribed, showcasing diverse IPO opportunities globally.

Global IPO markets are active with diverse listings planned across regions. Hong Kong anticipates large offerings from Kayou ($500M) and Mixue ($443M), while Malaysia's Eco-Shop eyes $212M. Oman's Asyad Shipping targets $333M, and Abu Dhabi's Alpha Data, $163M. Saudi Arabia expects a record IPO year. In the US, Redcloud revives a smaller offering. Europe sees potential listings from Swedish SBB and German OLB, with Shein considering London amidst valuation pressures. Singapore aims to attract Chinese listings.

Global IPO activity is high, especially in the US with Klarna's potential $15B IPO. Asia-Pacific is highlighted by JX Advanced Metal's potential record $3B Japan IPO and Mixue's $500M HK listing. Europe sees Novo Banco's €5B IPO and London vying for listings like IVC Evidensia and CurrentBody.

IPOX® CEO Josef Schuster commented in a recent Reuters article, "Karman Holdings valued at nearly $4 billion as shares jump in NYSE debut", offering expert analysis on Karman Holdings' successful IPO and the broader market trends favoring defense and space companies.

IPOX® CEO Josef Schuster was quoted in a recent Reuters article, "Cybersecurity firm SailPoint sets sights on $12.6 billion valuation in US IPO", providing expert insight into SailPoint's IPO and the broader implications for the technology IPO market.

Robust global IPO activity across multiple sectors: Significant US listings include SailPoint, projecting an $11.5B valuation, and DailyPay, targeting $3-4B. Honeywell's planned spin-offs represent a notable corporate restructuring. European markets are active, featuring Novo Banco and CurrentBody. In Asia, MMC Port's anticipated $1.34B Malaysian IPO highlights the region's strength. The Middle East maintains a positive outlook, with Saudi Arabia driving deal flow.

IPOX® Research Analyst Lukas Muehlbauer offered his perspective on the market debut of Maze Therapeutics (MAZE.O), a drug developer focused on chronic kidney diseases. Maze's shares saw a modest 1% increase on its Nasdaq debut, valuing the company at $690.37 million. The company’s debut follows an upsized IPO that raised $140 million.

Large potential IPOs are emerging across regions. In the US, Silvus considers a $5B valuation IPO, while Histosonics aims for a multi-billion dollar valuation. SailPoint eyes a $1B Nasdaq return. Europe sees EcoCeres planning a $5B IPO and HBX Group with strong book coverage for its Amsterdam listing.

IPOX® Research Analyst Lukas Muehlbauer offered his expert perspective on the market debut of Metsera, a GLP-1 weight-loss drug developer that achieved a $2.7 billion valuation following a 42% surge in its Nasdaq IPO. Metsera's strong performance underscores the robust investor appetite within the innovative obesity therapeutics sector.